Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Long-term Immune, Neurobiological, and Gut-vaginal-urinary axis Exhaustion post-UTI: Research and Rehabilitation

Ziel

Urinary tract infections (UTIs) affected an estimated 404.6 million people globally in 2019, contributing to nearly 236,786 deaths and 5.2 million Disability-Adjusted Life Years. For a substantial subset of patients (approximately 25–70% of women), a first UTI is not an isolated event but the beginning of a self-reinforcing cycle of recurrence, repeated antibiotic exposure, microbiome disruption, and epithelial vulnerability. The LINGER project (Long-term Immune, Neurobiological, and Gut–vaginal–urinary axis Exhaustion post-UTI: Research and Rehabilitation) aims to provide the first comprehensive molecular characterisation of this post-infection recurrence state and to deliver diagnostic tools, validated interventions, and structured rehabilitation strategies to transform its management.

LINGER is structured around three objectives. (1) Map & Stratify: establish a pan-European cohort of pre-menopausal women (18–50 years) across Germany, the Netherlands, and Italy, and apply integrated multi-omics (targeted genome sequencing, metagenomics, metatranscriptomics, proteomics/peptidomics, epigenomics, and metabolic modelling) and AI-driven analysis to develop the Virtual Urinary-Tract Twin, a predictive model of post-infection recurrence risk. (2) Dissect & Validate: use in vitro (3D urothelial models) and in vivo (mouse rUTI models) systems to identify and validate causal mechanisms. (3) Intervene & Empower: translate findings into a precision Bacterial-Like Particle (BLiP) mucosal immunotherapy, pilot a digital-first patient self-management and education platform (Post-UTI Recovery Programme), and conduct a comprehensive burden-of-illness assessment to support healthcare integration.

By delivering a predictive diagnostic tool, a Phase 1-ready immunotherapy candidate, and an evidence-based digital care platform, LINGER will shift rUTI management from reactive antibiotic use to proactive, precision prevention, advancing innovations from TRL 2–3 to TRL 4–5.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-RIA - HORIZON Research and Innovation Actions

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-HLTH-2026-01

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

JUSTUS-LIEBIG-UNIVERSITAET GIESSEN
Netto-EU-Beitrag
€ 1 084 372,50
Adresse
LUDWIGSTRASSE 23
35390 GIESSEN
Deutschland
Region
Berlin Berlin Berlin
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Beteiligte (13)